Current Cancer Drug Targets
Title:Meet Our Editorial Board Member
Volume: 16 Issue: 7
Author(s): Thomas W. Grunt
Affiliation:
Export Options
About this article
Cite this article as:
Grunt W. Thomas, Meet Our Editorial Board Member, Current Cancer Drug Targets 2016; 16 (7) . https://dx.doi.org/10.2174/156800961607160812205800
DOI https://dx.doi.org/10.2174/156800961607160812205800 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books
Article Metrics

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trefoil Factor Family (TFF) Peptides and their Different Roles in the Mucosal Innate Immune Defense and More: An Update
Current Medicinal Chemistry Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy Bio-analytical Identification of Key Genes that Could Contribute to the Progression and Metastasis of Osteosarcoma
Current Bioinformatics Meningioma in an Elderly Presenting as Psychosis: A Case Report
Clinical Cancer Drugs Synthesis, Biological Evaluation and Molecular Docking Studies Against EGFR Tyrosine Kinase of 3,5-bis(substituted benzylidene)-1- ethylpiperidin-4-one Analogues
Letters in Organic Chemistry Macrolides as Immunomodulatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Harmine Induces Gastric Cancer Cell Apoptosis through the ROSmediated PI3K/AKT Signaling Pathway
Current Signal Transduction Therapy Editorial: The Real Impact of Target Therapy in Cancer Patients: Between Hope and Reality
Current Cancer Drug Targets Epigenetic Regulation of Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Angiogenesis New Targets for the Development of Anticancer Chemotherapies
Current Pharmaceutical Design Melanogenesis and Melanosome Transportation Modulators from Medicinal Plants
Letters in Drug Design & Discovery Recent Advances in Gene Therapy of Endometriosis
Recent Patents on DNA & Gene Sequences Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Seeds of Mung Bean (<i>Vigna radiata</i> (L.) R.Wilczek): Taxonomy, Phytochemistry, Medicinal Uses and Pharmacology
Current Bioactive Compounds Suppression of Oncoprotein Her-2 and DNA Damage after Treatment with Flavan-3- ol Vitis labrusca Extract
Anti-Cancer Agents in Medicinal Chemistry Targeted Blood-to-Brain Drug Delivery – 10 Key Development Criteria
Current Pharmaceutical Biotechnology Role of microRNAs in Gynecological Pathology
Current Medicinal Chemistry The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer
Current Pharmaceutical Design New Hybrid Scaffolds Based on Carbazole-Chalcones as Potent Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Current Medicinal Chemistry